This is a revised proposal for a randomized comparison of the safety and accuracy of transabdominal amniocentesis and transabdominal CVS, each done during the same modified gestational age window of 77-104 days post last menstrual period (LMP) in contrast to 105-125 days post LMP for amniocentesis and 63-76 days post LMP for CVS. A consortium of 12 experienced prenatal diagnostic centers has been formed to facilitate patient acquisition and completion of the proposed project in a timely fashion. The group includes as principal investigators researchers with expertise in obstetrics, medical genetics, cytogenetics, pediatrics, epidemiology, biostatistics, and the conduct of cooperative clinical trials.
The specific aims for the study are to compare transabdominal amniocentesis and CVS at 77-104 days gestation with respect to: Preterm delivery or fetal loss from cytogenetically normal pregnancies, at less than 28 completed gestational weeks; total fetal loss including neonatal death before discharge; Amniotic fluid loss resulting in a pocket of less than 1 cm; gestational age at delivery; perinatal morbidity: intrauterine growth retardation (IUGR), neonatal respiratory problems and other complications; limb defects and other congenital anomalies of the newborn; failure to obtain a sample for diagnosis; failure to obtain a diagnosis; cytogenetic accuracy for diagnosis of abnormal karyotype (by standard culture methods); the diagnostic accuracy and applicability of fluorescence in situ hybridization (FISH) in CVS and amniotic fluid samples, as compared with standard methods; the accuracy of amniotic fluid alphafetoprotein and acetylcholinesterase at 77-104 days gestation for diagnosis of neural tube defects.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD031991-02
Application #
2403404
Study Section
Special Emphasis Panel (SRC (JT))
Project Start
1996-09-16
Project End
1999-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Goetzl, Laura (2010) Adverse pregnancy outcomes after abnormal first-trimester screening for aneuploidy. Clin Lab Med 30:613-28
Silver, Richard K; Wilson, R Douglas; Philip, John et al. (2005) Late first-trimester placental disruption and subsequent gestational hypertension/preeclampsia. Obstet Gynecol 105:587-92
Philip, J; Silver, R K; Wilson, R D et al. (2005) [Late first-trimester invasive prenatal diagnosis--secondary publication. An international randomized trial] Ugeskr Laeger 167:1293-6
Wapner, Ronald J (2005) First trimester screening: the BUN study. Semin Perinatol 29:236-9
Bahado-Singh, Ray O; Wapner, Ronald; Thom, Elizabeth et al. (2005) Elevated first-trimester nuchal translucency increases the risk of congenital heart defects. Am J Obstet Gynecol 192:1357-61
Goetzl, Laura; Krantz, David; Simpson, Joe Leigh et al. (2004) Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 104:30-6
Philip, J; Silver, R K; Wilson, R D et al. (2004) Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. Obstet Gynecol 103:1164-73
Platt, Lawrence D; Greene, Naomi; Johnson, Anthony et al. (2004) Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 104:661-6
Krantz, David; Goetzl, Laura; Simpson, Joe Leigh et al. (2004) Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191:1452-8
Wapner, Ronald; Thom, Elizabeth; Simpson, Joe Leigh et al. (2003) First-trimester screening for trisomies 21 and 18. N Engl J Med 349:1405-13